Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington’s disease
- I Reuter1,
- Y F Tai2,
- N Pavese2,
- K R Chaudhuri1,
- S Mason3,
- C E Polkey1,
- C Clough1,
- D J Brooks2,
- R A Barker3,
- P Piccini2
- 1 Academic Department of Neuroscience, Kings College Hospital, London, UK
- 2 Neurology Group, MRC Clinical Sciences Centre, Cyclotron Building, Imperial College London, Hammersmith Hospital, London, UK
- 3 Cambridge Centre for Brain Repair and Department of Neurology, Forvie Site, Cambridge, UK
- Dr P Piccini, Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK;
- Received 13 December 2007
- Revised 31 January 2008
- Accepted 10 February 2008
- Published Online First 20 March 2008
Two patients with moderate Huntington’s disease (HD) received bilateral fetal striatal allografts. One patient demonstrated, for the first time, increased striatal D2 receptor binding, evident with 11C-raclopride positron emission tomography, and prolonged clinical improvement over 5 years, suggesting long term survival and efficacy of the graft. The other patient did not improve clinically or radiologically. Our results indicate that striatal transplantation in HD may be beneficial but further studies are needed to confirm this.
The appendix is published online only at http://jnnp.bmj.com/content/vol79/issue8
Funding: The study was funded by the Medical Research Council, UK. YFT was funded by the Wellcome Trust (GR071659AIA).
Competing interests: None.
Ethics approval: The study received approval from the local research ethics committees.